U.S. markets closed
  • S&P 500

    4,567.00
    -88.27 (-1.90%)
     
  • Dow 30

    34,483.72
    -652.22 (-1.86%)
     
  • Nasdaq

    15,537.69
    -245.14 (-1.55%)
     
  • Russell 2000

    2,198.91
    -43.07 (-1.92%)
     
  • Crude Oil

    67.00
    -2.95 (-4.22%)
     
  • Gold

    1,776.20
    -9.00 (-0.50%)
     
  • Silver

    22.86
    +0.01 (+0.06%)
     
  • EUR/USD

    1.1346
    +0.0053 (+0.47%)
     
  • 10-Yr Bond

    1.4430
    -0.0870 (-5.69%)
     
  • GBP/USD

    1.3297
    -0.0015 (-0.11%)
     
  • USD/JPY

    113.0990
    -0.5090 (-0.45%)
     
  • BTC-USD

    57,301.43
    -985.87 (-1.69%)
     
  • CMC Crypto 200

    1,456.40
    +13.62 (+0.94%)
     
  • FTSE 100

    7,059.45
    -50.50 (-0.71%)
     
  • Nikkei 225

    27,821.76
    -462.16 (-1.63%)
     

aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Management to host conference call and webcast at 5:00 pm EST / 2:00 pm PST

SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2020 financial results after the market close on Thursday, March 26, 2020. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Thursday, March 26 @ 5:00 p.m. EDT / 2:00 p.m. PDT
Domestic: 844-358-9116
International: 209-905-5951
Conference ID: 1668357
Webcast: http://investors.atyrpharma.com/events-and-webcasts

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:

Joyce Allaire

Managing Director, LifeSci Advisors, LLC

jallaire@lifesciadvisors.com